Publications by authors named "C Lenormand"
Objectives: To investigate factors associated with dermatomyositis (DM) complete clinical response and overall survival with a focus on the use of immunosuppressive therapies in patients with cancer-associated DM.
Methods: We performed a multicentre, retrospective cohort study. Multivariable survival analyses used a Cox model with time-dependent covariates and adjustments with inverse probability censoring weighting.
Objectives: We have developed targeted proteomics in the context of Lyme borreliosis (LM) as a new direct diagnostic tool for detecting Borrelia proteins in the skin of patients with erythema migrans. If satisfactory, this proteomic technique could be used in addition to culture and/or PCR for disseminated infections where Borrelia detection is essential to demonstrate active infection. In these infections, the diagnosis is indirect and relies mainly on serology.
View Article and Find Full Text PDFArticle Synopsis
- Avelumab is a treatment approved for metastatic Merkel cell carcinoma (mMCC) and this study focused on its effectiveness in patients in France who received it as a second-line or later treatment.
- The study analyzed data from 180 patients, revealing a median overall survival of 14.6 months after starting avelumab and a 40.5% survival rate at 24 months.
- The results showed that real-world outcomes for avelumab align with previous clinical trial findings, reinforcing its recommendation as a standard treatment for mMCC.
Article Synopsis
- Recent findings show that mutations in the UBA1 gene are linked to VEXAS syndrome, an adult-onset auto-inflammatory condition, but the exact effects of these mutations are not well understood.
- Research on a group of VEXAS patients indicates that their monocytes are not functioning properly and exhibit signs of exhaustion and altered chemokine receptor expression.
- The study also highlights elevated levels of inflammatory cytokines in the blood of VEXAS patients, pointing to possible therapeutic targets related to inflammasome activation and inflammatory cell death.